Dianthus Therapeutics, Inc. (Nasdaq: DNTH) Delivers Strong Pipeline Progress and Reports Q4 & FY2025 Financial Results

Key Highlights and Business Achievements

• Early “GO” Decision in Phase 3 CAPTIVATE CIDP Trial: Dianthus achieved an early interim responder threshold in the registration-enabling Phase 3 CAPTIVATE trial of its lead asset, claseprubart (DNTH103), for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The “GO” criteria—20 confirmed responders—was met with fewer than 40 planned participants completing the open-label Part A. This milestone was reached ahead of prior Q2’26 guidance and could accelerate the development timeline for this pivotal program.
• Strong Cash Position: Dianthus reported \$514.4 million in cash, cash equivalents, and investments as of December 31, 2025. This robust capital runway is expected to fund operations into 2028, supporting multiple clinical milestones and reducing financing risk.
• Advancing Registrational Programs:
  • Generalized Myasthenia Gravis (gMG): Phase 3 registrational trial of claseprubart (300mg/2mL dosed Q2W and Q4W subcutaneously) is expected to initiate mid-2026, with top-line data anticipated in the second half of 2028. Preparations follow a successful end-of-Phase 2 meeting with the FDA in Q1 2026.
  • Multifocal Motor Neuropathy (MMN): The Phase 2 MoMeNtum trial with claseprubart remains on track, with top-line results expected in 2H’26.
• Pipeline Expansion:
  • DNTH212: This extended half-life bifunctional fusion protein targets both innate and adaptive immune pathways and is being evaluated in a two-part Phase 1 study (healthy volunteers and SLE patients) in China. Top-line results in healthy volunteers are expected in 2H’26, with forthcoming updates on indication prioritization in 1H’26.

Business and Clinical Pipeline Details

Claseprubart (DNTH103): A Potential Best-in-Class Neuromuscular Franchise

Claseprubart is a potent, selective monoclonal antibody engineered to inhibit only the active form of the C1s protein, a validated target in the classical complement pathway. Its design enables convenient, infrequent subcutaneous self-administration (once every two or four weeks) via an autoinjector.

The company aims for claseprubart to become a pipeline-in-a-product across multiple autoimmune indications, addressing significant unmet needs in diseases such as CIDP, gMG, and MMN. With a U.S. patient population exceeding 150,000 across these conditions, the commercial opportunity is considerable.

• gMG Program: Phase 3 to start mid-2026; top-line data expected in H2 2028. Recent Phase 2 MaGic data and in vitro results were presented at the Muscular Dystrophy Association conference in March 2026.
• CIDP Program: The early “GO” decision in the CAPTIVATE trial indicates a response rate of at least 50% at interim, setting a positive precedent for future aC1s inhibition therapies. Guidance for Part B top-line results is anticipated by year-end 2026.
• MMN Program: Phase 2 MoMeNtum study is ongoing, with key data expected in the second half of 2026.

Claseprubart also incorporates YTE half-life extension technology, potentially improving patient convenience and reducing infection risk by selectively preserving other immune pathways.

DNTH212: Novel Approach Targeting Dual Immune Pathways

DNTH212 is a bifunctional fusion protein designed to reduce Type 1 interferon production (via BDCA2) and suppress B cell function (via BAFF/APRIL inhibition). This dual-targeting mechanism offers a differentiated approach with potential across several autoimmune indications. A two-part Phase 1 study is underway in China, with top-line healthy volunteer data by 2H’26 and indication prioritization update in 1H’26.

Financial Results (Year Ended December 31, 2025)

• Total Revenues: \$2.0 million, down from \$6.2 million in 2024, reflecting a reduction in license revenue.
• R&D Expenses: \$145.6 million (including \$10.1 million in stock-based compensation), up significantly from \$83.1 million in 2024. The increase was driven by higher clinical trial costs, DNTH212 development milestones, and headcount growth to support advancing programs.
• G&A Expenses: \$34.3 million (including \$12.7 million in stock-based compensation), up from \$25.0 million, primarily due to increased personnel.
• Net Loss: \$162.3 million or \$4.20 per share (basic and diluted), compared to \$85.0 million or \$2.55 per share in 2024, reflecting increased investment in pipeline development.
• Cash and Investments: \$514.4 million as of year-end 2025, providing a projected runway into 2028.

Upcoming Catalysts & Shareholder Considerations

• Early positive interim data in the CAPTIVATE CIDP trial suggests a potentially accelerated path to market for claseprubart, which could be transformative for patients and create substantial value for shareholders if later-stage results are consistent.
• Initiation of Phase 3 gMG program and multiple data readouts (gMG, MMN, DNTH212) represent significant upcoming clinical catalysts; successful outcomes could drive share price appreciation.
• Strong cash position mitigates financing risk and supports continued pipeline execution through major value inflection points.
• Risks include: Clinical development setbacks, regulatory delays, or negative data in ongoing or future trials could materially impact the company’s valuation. The company explicitly cautions that early trial results and preclinical data may not be predictive of future success.

Investor Events

Dianthus Therapeutics will host an investor conference call and webcast to discuss the CAPTIVATE trial interim responder analysis on March 9, 2026, at 8:00 a.m. ET. Investors can access the live webcast via the company’s website, with a replay available afterward.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases. With a leadership team experienced in biotech and pharma, Dianthus aims to deliver transformative medicines for patients with significant unmet medical needs.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements in this article are based on company disclosures and may be subject to risks and uncertainties that could cause actual results to differ materially. Investors should consult the company’s filings with the SEC and speak with a qualified financial advisor before making investment decisions.

View Dianthus Therapeutics, Inc. /DE/ Historical chart here